Musculoskeletal InjuryNCT03880981
NSAID Use and Healing After Tibia Fractures and Achilles Tendon Ruptures
A study testing Ibuprofen 600 mg and Acetaminophen in people with Musculoskeletal Injury, run by University of California, Los Angeles.
Trial summary
Rationale: The Emergency Department (ED) typically serves as the front line for patients with acute fractures and tendon ruptures. Pain control for these patients is an essential task of the ED physician. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Musculoskeletal Injury
- What is being tested?
- Ibuprofen 600 mg and Acetaminophen
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 456 participants
- Where
- No sites listed yet
- Study dates
- 1 Aug 2019to 31 Jul 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adult patients (over 18) presenting within 24 hours of a tibia fracture
- Adult patients (over 18) presenting within 24 hours of an Achilles tendon rupture
- Exclusions:
- Patients will be excluded if they:
- have a contraindication to Ibuprofen or Acetaminophen use
- don't have access to e-mail
Show all 11Show fewer
- require emergent surgery (such as an open fracture)
- have a diagnosis of osteoporosis
- have already taken one of the study drugs since their injury
- are pregnant (due to their inability to take NSAIDs)
- are < 18 years old (due to differences in bone and tendon healing).
Who cannot join
None listed.
Trial locations and contacts
No sites are listed yet.
About this study
Rationale: The Emergency Department (ED) typically serves as the front line for patients with acute fractures and tendon ruptures. Pain control for these patients is an essential task of the ED physician. With the advent of the opioid epidemic, ED physicians are becoming more inclined to prescribe non-narcotic pain medications such as non-steroidal anti-inflammatory drugs (NSAIDs). Yet, the effects of NSAIDs on musculoskeletal healing are controversial. The few human studies examining the effects of NSAID use on fracture healing have provided conflicting results. Even less is known about the effects of NSAIDs on tendon healing as this information has largely been gleaned from rodent studies with contradictory findings. There has never been a large, prospective, randomized, double-blinded study to determine the effects of NSAIDs on healing after fractures or tendon ruptures. Here, I propose to pilot the first prospective, randomized, double-blinded study examining the effects of NSAID use on healing after tibia fractures and Achilles tendon ruptures.
Aim 1 seeks to determine whether NSAID use is associated with an increased incidence of fracture nonunion and worse functional recovery six months following tibia fractures. I hypothesize that NSAID use after tibia fractures will be associated with an increased incidence of fracture nonunion and worse functional recovery. Aim 2 seeks to determine whether NSAID use is associated with worse functional recovery six months after Achilles tendon ruptures. I hypothesize that NSAID use after Achilles tendon ruptures will be associated with worse functional recovery.
Significance: Emergency Department providers commonly prescribe NSAIDs for pain control following fractures and tendon injuries. However, the implications of this practice on bone and tendon healing are unknown. This proposal will pilot the first prospective, randomized, double-blinded study to determine whether NSAID use affects healing after tibia fractures and Achilles tendon ruptures. Results from this study will impact NSAID prescribing patterns for tibia fractures and Achilles tendon ruptures in the ED, either by demonstrating that they impair recovery and should be avoided, or that they need not be withheld as an effective non-narcotic form of pain control.
Read the detailed description
Specific Aims The Emergency Department (ED) typically serves as the front line for patients with fractures and tendon ruptures. Pain control for these patients is an essential task of the ED physician. With the advent of the opioid epidemic, ED physicians are becoming more inclined to prescribe non-narcotic pain medications such as non-steroidal anti-inflammatory drugs (NSAIDs). Yet, the effects of NSAIDs on musculoskeletal healing are highly controversial. There is some evidence that NSAIDs may prevent osteoblasts from rebuilding bone after fractures by inhibiting COX-2. Indeed, some retrospective studies have found NSAID use to be associated with an increased incidence of fracture nonunion after acetabular, tibial, and humeral shaft fractures, while other studies reported no difference. The only prospective randomized controlled trials evaluating the effects of NSAIDs on fracture healing reported no effect of NSAID use on healing after Colles fractures; however, these trials were likely underpowered to detect a difference in nonunion rates. Here, I propose to pilot the first large, prospective, randomized, double-blinded study examining the effects of NSAIDs on healing after tibia fractures, which are vulnerable to nonunion.
Similar to fractures, the effects of NSAIDs on tendon healing are unclear. Some studies suggest that NSAIDs may inhibit proliferation and migration of tendon cells after injury, while other studies indicate that NSAIDs enhance collagen synthesis. Rodent studies are equally conflicting, with some reports of worse outcomes associated with NSAID use and other studies showing no difference. Recently, I obtained preliminary data showing that NSAID use after Achilles tendon ruptures is associated with worse functional outcomes as measured by the Achilles Tendon Total Rupture Score (ATRS). While this was the first study examining the effects of NSAID use on recovery after Achilles tendon rupture in humans, the data were retrospective, observational, and not blinded. Here, I propose to pilot the first prospective, randomized, double-blinded study to determine the effects of NSAIDs on recovery after Achilles tendon ruptures.
Aim 1: Determine whether NSAID use is associated with an increased incidence of fracture nonunion and worse functional recovery six months after tibia fractures.
Hypothesis: I hypothesize that NSAID use after tibia fractures will be associated with an increased incidence of fracture nonunion and worse functional recovery.
Aim 2: Determine whether NSAID use is associated with worse functional recovery six months after Achilles tendon ruptures.
Hypothesis: I hypothesize that NSAID use after Achilles tendon ruptures will be associated with worse functional recovery.
Experimental Approach: Adult patients (18 years old and over) presenting to either the University of California Los Angeles (UCLA) Ronald Regan Emergency Department, the UCLA Santa Monica Emergency Department, or the UCLA Orthopedic after hours acute care clinic within 24 hours of sustaining a tibia fracture or Achilles tendon rupture will be screened for eligibility to participate. Patients will be excluded if they have a contraindication to Ibuprofen or Acetaminophen use, if they do not have access to e-mail, if they do not wish to participate, if they require emergent surgery (such as an open fracture), if they have a diagnosis of osteoporosis, or if they have already taken pain medication since their injury. Pregnant women will be excluded due to their inability to take NSAIDs. Children will be excluded due to differences in bone and tendon healing. The ED represents the optimal environment in which to conduct this study because most patients will initially present acutely to the ED with these injuries, often before taking any pain medication.
If patients elect to participate, they will be randomized to receive either Ibuprofen (600mg by mouth every 6 hours as needed for pain) or Acetaminophen (650 mg by mouth every 6 hours as needed for pain). I will use a permuted block design to develop the randomization schedule. Randomization will be stratified by sex. Sealed envelopes will be used to conceal the allocation. The treating physician will open the envelope and provide the assigned study medication and prescription bottle at discharge. Patients will be provided a one-month supply of their assigned pain medication. Patients and providers will be blinded to which medication the patient received. The individual medication capsules will be formulated to lack identifying information. Study coordinators will record the patients' randomly generated study identification number and prescription bottle number in Qualtrics, a HIPAA-compliant online resource that collects, stores, and analyzes data. Demographic information such as age and sex will also be stored in Qualtrics. Each week for one month, patients will be sent an email with a link asking them to complete a Qualtrics survey to report 1) the number of remaining pills, 2) their average pain scale ranging from 1-9, 3) what additional medications they took, if any, and 4) whether they have experienced any medication-related side effects or complications. In this way, we will determine the timing of medication administration for each patient and quantify each patient's level of pain, while assessing for patient safety.
Six months post-injury, patients who sustained tibia fractures will receive repeat X-rays. One final Qualtrics survey will be e-mailed to these patients at this time to determine their average degree of pain on a scale of 1-9, their functional recovery on a scale of 1 to 3 (mild, moderate, or severe impairment) and whether they underwent treatments such as physical therapy or surgery. The survey will also assess for lifestyle factors known to increase nonunion rates including body habitus, medical problems, and other medications taken.
Six months following enrollment, patients who ruptured their Achilles tendon will be sent a link to a Qualtrics survey via email. On this survey, they will be asked 10 questions with responses on a scale of 0 to 10 that comprise the ATRS (29). A higher score (out of 100) indicates better functional outcomes. Patients will also be asked if they underwent treatments such as physical therapy or surgery. Body habitus, medical problems, other medications taken, smoking status, pregnancy status, and fluoroquinolone use will also be assessed on this survey, as these factors may impact tendon recovery.
- Conditions
- Musculoskeletal Injury
- Being tested
- Ibuprofen 600 mg, Acetaminophen
- Keywords
- fracture, tendon rupture, NSAID, healing
- Medical subject headings
- Fractures, Bone
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ibuprofen 600 mgDrug
ibuprofen 600mg Po q 6 hours prn pain
AcetaminophenDrug
acetaminophen 600mg po q6 hours prn pain
| Study group | Role | What they receive |
|---|---|---|
| Acetaminophen | Active comparator | Patients will receive 650mg PO Acetaminophen every 6 hours as needed for pain Receives: Drug: Acetaminophen |
| Ibuprofen | Active comparator | Patients will receive 600mg PO Ibuprofen every 6 hours as needed for pain Receives: Drug: Ibuprofen 600 mg |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of non-union after tibia fracture
Fractures
Measured: 6 months
Functional Recovery after Achilles Tendon Rupture
Achilles Tendon Total Rupture Score measures functional recovery after Achilles tendon rupture on a scale of 0 (worse) to 100 (best).
Measured: 6 months
Secondary outcomes (2)
Functional Impairment after Tibia Fracture on a scale of 1 to 3 (none to severe)
The score quantifies functional impairment on a scale of 1 (none) to 3 (severe)
Measured: 6 months
Degree of pain after Tibia Fracture on a scale of 1-9
The score quantifies pain on a scale of 1 (none) to 9 (severe)
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Mar 2019
- Study start1 Aug 2019 (estimated)
- Primary completion31 Jul 2020 (estimated)
- Study completion31 Jul 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Musculoskeletal InjuryStudies of the same condition, open and under way.
- More trials run by University of California, Los AngelesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 456 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of California, Los Angeles
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Vanessa Franco, MD, PhD, University of California, Los Angeles
- Investigators
- Vanessa Franco, MD PhD, Principal investigator, Assistant Professor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03880981
- Sponsor's protocol ID
- VFranco
- Status last verified
- Mar 2019
- First submitted
- 22 Feb 2019
- Last updated
- 19 Mar 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- NSAID Use and Healing After Tibia Fractures and Achilles Tendon Ruptures
- ClinicalTrials.gov ID
- NCT03880981
- Acronym / sponsor ID
- VFranco
- Conditions
- Musculoskeletal Injury
- Keywords
- fracture, tendon rupture, NSAID, healing
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 456 participants (estimated)
- Lead sponsor
- University of California, Los AngelesUniversity, hospital or other
- Study start
- 1 Aug 2019 (estimated)
- Primary completion
- 31 Jul 2020 (estimated)
- Study completion
- 31 Jul 2020 (estimated)
- First posted
- 19 Mar 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Rationale: The Emergency Department (ED) typically serves as the front line for patients with acute fractures and tendon ruptures. Pain control for these patients is an essential task of the ED physician. With the advent of the opioid epidemic, ED physicians are becoming more inclined to prescribe non-narcotic pain medications such as non-steroidal anti-inflammatory drugs (NSAIDs). Yet, the effects of NSAIDs on musculoskeletal healing are controversial. The few human studies examining the effects of NSAID use on fracture healing have provided conflicting results. Even less is known about the effects of NSAIDs on tendon healing as this information has largely been gleaned from rodent studies with contradictory findings. There has never been a large, prospective, randomized, double-blinded study to determine the effects of NSAIDs on healing after fractures or tendon ruptures. Here, I propose to pilot the first prospective, randomized, double-blinded study examining the effects of NSAID use on healing after tibia fractures and Achilles tendon ruptures.
Aim 1 seeks to determine whether NSAID use is associated with an increased incidence of fracture nonunion and worse functional recovery six months following tibia fractures. I hypothesize that NSAID use after tibia fractures will be associated with an increased incidence of fracture nonunion and worse functional recovery. Aim 2 seeks to determine whether NSAID use is associated with worse functional recovery six months after Achilles tendon ruptures. I hypothesize that NSAID use after Achilles tendon ruptures will be associated with worse functional recovery.
Significance: Emergency Department providers commonly prescribe NSAIDs for pain control following fractures and tendon injuries. However, the implications of this practice on bone and tendon healing are unknown. This proposal will pilot the first prospective, randomized, double-blinded study to determine whether NSAID use affects healing after tibia fractures and Achilles tendon ruptures. Results from this study will impact NSAID prescribing patterns for tibia fractures and Achilles tendon ruptures in the ED, either by demonstrating that they impair recovery and should be avoided, or that they need not be withheld as an effective non-narcotic form of pain control.
Detailed description
Specific Aims The Emergency Department (ED) typically serves as the front line for patients with fractures and tendon ruptures. Pain control for these patients is an essential task of the ED physician. With the advent of the opioid epidemic, ED physicians are becoming more inclined to prescribe non-narcotic pain medications such as non-steroidal anti-inflammatory drugs (NSAIDs). Yet, the effects of NSAIDs on musculoskeletal healing are highly controversial. There is some evidence that NSAIDs may prevent osteoblasts from rebuilding bone after fractures by inhibiting COX-2. Indeed, some retrospective studies have found NSAID use to be associated with an increased incidence of fracture nonunion after acetabular, tibial, and humeral shaft fractures, while other studies reported no difference. The only prospective randomized controlled trials evaluating the effects of NSAIDs on fracture healing reported no effect of NSAID use on healing after Colles fractures; however, these trials were likely underpowered to detect a difference in nonunion rates. Here, I propose to pilot the first large, prospective, randomized, double-blinded study examining the effects of NSAIDs on healing after tibia fractures, which are vulnerable to nonunion.
Similar to fractures, the effects of NSAIDs on tendon healing are unclear. Some studies suggest that NSAIDs may inhibit proliferation and migration of tendon cells after injury, while other studies indicate that NSAIDs enhance collagen synthesis. Rodent studies are equally conflicting, with some reports of worse outcomes associated with NSAID use and other studies showing no difference. Recently, I obtained preliminary data showing that NSAID use after Achilles tendon ruptures is associated with worse functional outcomes as measured by the Achilles Tendon Total Rupture Score (ATRS). While this was the first study examining the effects of NSAID use on recovery after Achilles tendon rupture in humans, the data were retrospective, observational, and not blinded. Here, I propose to pilot the first prospective, randomized, double-blinded study to determine the effects of NSAIDs on recovery after Achilles tendon ruptures.
Aim 1: Determine whether NSAID use is associated with an increased incidence of fracture nonunion and worse functional recovery six months after tibia fractures.
Hypothesis: I hypothesize that NSAID use after tibia fractures will be associated with an increased incidence of fracture nonunion and worse functional recovery.
Aim 2: Determine whether NSAID use is associated with worse functional recovery six months after Achilles tendon ruptures.
Hypothesis: I hypothesize that NSAID use after Achilles tendon ruptures will be associated with worse functional recovery.
Experimental Approach: Adult patients (18 years old and over) presenting to either the University of California Los Angeles (UCLA) Ronald Regan Emergency Department, the UCLA Santa Monica Emergency Department, or the UCLA Orthopedic after hours acute care clinic within 24 hours of sustaining a tibia fracture or Achilles tendon rupture will be screened for eligibility to participate. Patients will be excluded if they have a contraindication to Ibuprofen or Acetaminophen use, if they do not have access to e-mail, if they do not wish to participate, if they require emergent surgery (such as an open fracture), if they have a diagnosis of osteoporosis, or if they have already taken pain medication since their injury. Pregnant women will be excluded due to their inability to take NSAIDs. Children will be excluded due to differences in bone and tendon healing. The ED represents the optimal environment in which to conduct this study because most patients will initially present acutely to the ED with these injuries, often before taking any pain medication.
If patients elect to participate, they will be randomized to receive either Ibuprofen (600mg by mouth every 6 hours as needed for pain) or Acetaminophen (650 mg by mouth every 6 hours as needed for pain). I will use a permuted block design to develop the randomization schedule. Randomization will be stratified by sex. Sealed envelopes will be used to conceal the allocation. The treating physician will open the envelope and provide the assigned study medication and prescription bottle at discharge. Patients will be provided a one-month supply of their assigned pain medication. Patients and providers will be blinded to which medication the patient received. The individual medication capsules will be formulated to lack identifying information. Study coordinators will record the patients' randomly generated study identification number and prescription bottle number in Qualtrics, a HIPAA-compliant online resource that collects, stores, and analyzes data. Demographic information such as age and sex will also be stored in Qualtrics. Each week for one month, patients will be sent an email with a link asking them to complete a Qualtrics survey to report 1) the number of remaining pills, 2) their average pain scale ranging from 1-9, 3) what additional medications they took, if any, and 4) whether they have experienced any medication-related side effects or complications. In this way, we will determine the timing of medication administration for each patient and quantify each patient's level of pain, while assessing for patient safety.
Six months post-injury, patients who sustained tibia fractures will receive repeat X-rays. One final Qualtrics survey will be e-mailed to these patients at this time to determine their average degree of pain on a scale of 1-9, their functional recovery on a scale of 1 to 3 (mild, moderate, or severe impairment) and whether they underwent treatments such as physical therapy or surgery. The survey will also assess for lifestyle factors known to increase nonunion rates including body habitus, medical problems, and other medications taken.
Six months following enrollment, patients who ruptured their Achilles tendon will be sent a link to a Qualtrics survey via email. On this survey, they will be asked 10 questions with responses on a scale of 0 to 10 that comprise the ATRS (29). A higher score (out of 100) indicates better functional outcomes. Patients will also be asked if they underwent treatments such as physical therapy or surgery. Body habitus, medical problems, other medications taken, smoking status, pregnancy status, and fluoroquinolone use will also be assessed on this survey, as these factors may impact tendon recovery.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Acetaminophen | Active comparator | Drug: AcetaminophenPatients will receive 650mg PO Acetaminophen every 6 hours as needed for pain |
| Ibuprofen | Active comparator | Drug: Ibuprofen 600 mgPatients will receive 600mg PO Ibuprofen every 6 hours as needed for pain |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Adult patients (over 18) presenting within 24 hours of a tibia fracture
- Adult patients (over 18) presenting within 24 hours of an Achilles tendon rupture
- have a contraindication to Ibuprofen or Acetaminophen use
- don't have access to e-mail
- require emergent surgery (such as an open fracture)
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ibuprofen 600 mgibuprofen 600mg Po q 6 hours prn pain | Drug | Ibuprofen |
| Acetaminophenacetaminophen 600mg po q6 hours prn pain | Drug | Acetaminophen |
Primary outcome
Incidence of non-union after tibia fracture
Time frame: 6 months
Fractures
Functional Recovery after Achilles Tendon Rupture
Time frame: 6 months
Achilles Tendon Total Rupture Score measures functional recovery after Achilles tendon rupture on a scale of 0 (worse) to 100 (best).
2 secondary outcomes
Functional Impairment after Tibia Fracture on a scale of 1 to 3 (none to severe)
Time frame: 6 months
Degree of pain after Tibia Fracture on a scale of 1-9
Time frame: 6 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2019.
- Individual participant dataSharing planned: No
Related trials for Musculoskeletal Injury
Recruiting
Effects of Cervicothoracic Mobilization in Patients With Supraspinatus Tendinitis
Rotator Cuff Tendonitis
Recruiting
SIRI Levels Following PENG Block in Pediatric Hip Surgery
Hip Dysplasia
RecruitingPhase 4
PENG With LFCB vs. ESP Blocks for Pediatric Hip Surgery
Hip Disease, Hip Dysplasia
RecruitingObservational study
Exploring Factors Linked to Worsening Over Time in People With Early-stage Knee Osteoarthritis and Those With Prior Proven Acute Knee Injury.
Knee Osteoarthritis
Not yet recruiting
TECAR With Shoulder Chronic Shoulder Impingement Syndrome
Shoulder Impingement Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Vanessa Franco, MD PhD principal investigator
Assistant Professor
Questions about this trial
What is this clinical trial studying?
A study testing Ibuprofen 600 mg and Acetaminophen in people with Musculoskeletal Injury, run by University of California, Los Angeles.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 19 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Vanessa Franco, MD PhD ((310) 794-0585, vfranco@mednet.ucla.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of non-union after tibia fracture (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2019.